The ACCESS CHINA Boston Forum, jointly organized by YAFO Capital, CHBD, CEIBS, ChemPartner, and Global Law Office, concluded successfully on June 4th at Seaport Hotel in Boston. This grand event brought together around 150 executives and BD representatives from pharmaceutical companies and investment institutions worldwide to discuss the latest trends and achievements in Asian countries such as China, Japan, and South Korea. The forum revolved around the theme of "Asian Innovation and Cross-border Partnering" and featured keynote speeches, panel discussions, company presentations, and the ChemPartner-ACCESS CHINA Reception Dinner, serving as an important platform for exchanges and cooperation in the pharmaceutical field.

The excitement of the ACCESS CHINA Boston Forum continues with a series of online roadshows from June 13th to 15th, providing participants with more opportunities for business negotiations and project showcases. For more information and registration, please visit BioToChina.org.

The opening speech was delivered by Mr. Sean Jiang, the CEO of YAFO Capital and Vice President of CHBD, who provided an overview and outlook on innovative drug research and development in China.

John Zeng, the CEO of ChemPartner, gave a keynote speech titled "Overview and Prospects of Innovative Drug Research and Development in China," sharing fascinating insights on the subject. 

Lei Zhou, the partner of Global Law Office, delivered a speech titled "Legal Issues in Cross-Border Licensing Transactions," delving into the legal challenges encountered in such transactions.

During the company roadshow session, representatives from innovative pharmaceutical companies presented their latest updates and projects. Here are some highlights:

Novamab: Dr. Wan Yakun, the CEO, presented the latest update on their leading inhaled nanobodies innovation. Novamab is a leading innovator in inhaled nanobodies, focusing on the development of life-changing therapeutic drugs for patients. Their core expertise lies in the research and development of innovative single domain antibody (sdAb) drugs, aiming to make treatments for respiratory diseases more convenient and effective. With a pioneering inhaled large molecule drug development platform, Novamab targets a wide range of respiratory system diseases, including Asthma, COPD, IPF, CF, and more. Their clinical pipeline boasts two first-in-class sdAb inhaled products, currently in advanced stages of clinical development.

Astrocyte: CEO William Korinek introduced the company's innovative project focused on developing novel brain-protective therapies for patients with brain injuries. Their research primarily targets brain injuries caused by neurodegenerative diseases such as stroke, concussion, and Alzheimer's disease.

Chuangte Biotech: Their CEO presented their lead asset, a potential best-in-class RET mutation inhibitor for the treatment of various tumors. Chuangte Biotech is an innovative biopharmaceutical company specializing in innovative drug research, technology transfer, and the industrialization of pharmaceutical products. Their focus areas include oncology, cerebrovascular, and respiratory diseases, with a commitment to providing innovative products for patients.

TOSK: Represented by BD Director Mateo Needham, the company shared their research and development progress. TOSK is dedicated to developing new drugs that improve existing treatment regimens by reducing adverse reactions and enhancing safety and efficacy. They have recently developed a new technology for discovering drugs that can inhibit cancer gene activity.

Evive Biotech: A representative from Evive Biotech shared the latest update on their lead asset, a recombinant human IL-22 dimer fusion protein. Evive is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for oncology, inflammatory, and metabolic diseases using their proprietary technology platforms.

XtalPi: CSO Dr. Zhang Peiyu introduced the groundbreaking scientific advancements of the company to the attendees. XtalPi is an intelligent and automation-driven pharmaceutical research technology company that provides integrated solutions for drug discovery to global biopharmaceutical enterprises.

Elixiron: Founder & CMO Kevin Chen presented the update on the company and their lead asset anti-IFN-γ antibody.

Immunophage: CEO Guohuang Fan presented the latest developments of the company and their rich pipeline. Immunophage is a clinical stage biopharmaceutical company in China focused on immune regulation, discovering new targets and signalling pathways to precisely regulate the immune system, and providing the potentially best treatment options for malignant tumor, autoimmune diseases, neurodegenerative diseases and metabolic diseases.

During the Coffee break, participants exchanged and established contacts to further expand cooperation opportunities.

                                                   Coffee Break

 Video Promotion Of The Hainan Boao Lecheng International Medical Tourism Pilot Zone

After the coffee break, the wonderful roadshow continued. More company presentations was conducted, showing exciting innovations to everyone. Let's take a look at the speakers in this segment and the companies they represent: 

Diamedica: Company presentation conducted by CBO David Wambeke. The company's acute ischemic stroke drug is in phase III clinical trials.

PharmaSolux: Presented by Dr. Pan Shuang, Head of Bioanalysis and CMC Analysis Development.

Zytoprotec: Co-founder Christian Hoenig presented the company's project, a new formulation of glyco-based peritoneal dialysate, which can activate the protective mechanism of peritoneal cells and significantly reduce the side effects of peritoneal dialysis such as peritonitis and peritoneal failure.

QureBio: CEO Dr. Xiangdong Qu shared the latest update on their PD-L1/Claudin18.2 Bi-specific Antibody. Founded by experienced scientists from Eli Lily and Amgen, QureBio has built up a series of proprietary technologies for engineered bio-macromolecules and established on-going cooperation with industrial partners including Hengrui Pharmaceuticals. With a track record of global drug development, the founding team has a profound understanding of oncology-immunology and rich experience.

Tavotek: CSO Mark Chiu presented their potential best-in-class anti-TSLP antibody and other novel assets. Tavotek is a Chinese biopharmaceutical company focusing on treatment of cancers, autoimmune conditions, and infectious diseases.

Spektar Therapeutics: CEO Zarvaan Merchant introduced to the attendees the company's sustained-release tablet project for depression.

MindRank: Sree Vadlamudi, Head of Strategy and Corporate Development, shared the latest updates on their AI platform and their small molecule agonist of GLP-1R asset. The company has a one-stop AI-driven drug discovery platform. Within a few months of its establishment, the company has carried out commercial cooperation with a number of listed pharmaceutical companies and has been recognized. 

In addition to the exciting roadshow sessions, we also had a panel discussion on "Building Effective Partnership in Asia: Strategies for Collaboration and Growth." This discussion was moderated by Kun Tao, US Head & Managing Partner of YAFO Capital. The panelists include Ying Niu, China Search and Evaluation Lead at Pfizer; Haru Sugino, Global Head of Search and Evaluation; and Global Business Development at Otsuka Pharmaceutical; Vishal Doshi, CEO of AUM Biosciences; and Li Zhu, CSO of Genscript. They explored strategies for establishing effective partnerships in Asia and shared valuable insights and takeaways for the attendees. 

We also provided the opportunity for one-on-one meetings with guests to further explore cooperation opportunities and in-depth exchanges.

In the evening, the ChemPartner-ACCESS CHINA Reception Dinner, sponsored by ChemPartner, was held to celebrate the successful forum. The dinner was hosted by Victor Ye, Head of YAFO Capital China Division. During the dinner, representatives from ChemPartner, Global Law Office, and YAFO Capital conducted three lucky draws. Congratulations to the fortunate winners!

The online roadshow will be held from June 13 to 15. For more information and to sign up, please visit BIOTOCHINA.ORG. 

Thank you for your support of ACCESS CHINA Boston Forum. We look forward to your visit and participation in the upcoming online events and next onsite conference during JPM conference in Jan 2024! Let us work together to promote pharmaceutical innovation worldwide and create a better future!

Special Thanks 

We would like to extend our special thanks to our sponsors and partners, who have made significant contributions to the success of this event. Their support has not only enabled us to provide high-quality content and excellent speakers but also provided valuable business opportunities and partnerships for the attendees. We would like to express our heartfelt gratitude to the following collaborators: 

ChemPartner

ChemPartner Group was founded on 26th Jan 2000 and publicly listed on the Shenzhen Stock Exchange in the year 2010, stock code 300149. The group now consists of 5 National Level High-tech Enterprises and has developed a research services team comprising of more than 1800 research personnel, 200 of which have obtained doctorate qualifications. With a pharmaceutical services and production platform based on the international standards of their biological and chemical drug research, a leading platform in microecological nutrition and interventions research, as well as being able to provide healthcare solutions based on microecological medical research, the employees at ChemPartner are able to fulfill their utmost potentials. With a core value of “Achievements Lie within Human Effort”, their mission is to bring microecological health and prosperity to the masses through assisting the development of the Chinese pharmaceutical industry, promoting innovation of the global healthcare industry and microecological technology.

Global Law Office

The history of Global Law Office (hereinafter the “GLO”) dates back to the establishment of China’s Legal Consultant Office of the Council for the Promotion of International Trade (hereinafter the “CCPIT”) in 1979. After years of persistent endeavours and development, we have become one of the largest and leading Chinese law firms.

As the earliest team focused on life science and medical field in China, Global's life science and medical team has rich project experience, adhering to the working philosophy and principle of attaching equal importance to legal compliance and commercial feasibility, adhering to the industry background and legal services. And they have provided clients with comprehensive legal support in the industry, including assisting clients to deal with mergers and acquisitions, investment and financing, licensing and introduction, foreign authorization, regular law, intellectual property protection business, as well as internal investigations, government investigations, anti-corruption and other compliance business.

China Europe International Business School (CEIBS)

China Europe International Business School (CEIBS) was co-founded by the Chinese government and European Union (EU) in 1994, with Shanghai Jiao Tong University and the EFMD serving as its executive partners. CEIBS has campuses in Shanghai, Beijing, Shenzhen, Zurich in Switzerland, and Accra in Ghana.

As China’s only business school to originate from government-level collaboration, CEIBS is committed to educating responsible leaders versed in ‘China Depth, Global Breadth’ in line with its motto of ‘Conscientiousness, Innovation and Excellence’. Leaders from the Chinese central government and the EU, respectively, have lauded CEIBS as “a cradle of excellent executives” and “a role model of EU-China co-operation”.

CEIBS offers MBA, Finance MBA, EMBA, Global EMBA, Hospitality EMBA, DBA (Switzerland), and Executive Education programmes. CEIBS was the first business school on the Chinese mainland to be accredited by both EQUIS and AACSB. CEIBS has placed #1 in Asia in the FT’s ranking of global MBA programmes for seven consecutive years, and has been ranked in the top 5 on its global EMBA list for five consecutive years.

The Hainan Boao Lecheng International Medical Tourism Pilot Zone

The Hainan Boao Lecheng International Medical Tourism Pilot Zone is the only "special medical zone" in China. The concession policy of it allows Chinese people to get the diagnosis and treatment of global advanced drugs and medical devices that have been approved abroad but have not been listed in China. And up to now, thanks to the zone, more than 310 kinds of innovative medical devices that are not listed in China can be used. The support of these partners allows us to provide a rich and diverse forum that fosters collaboration and development in the pharmaceutical industry. 

Contact us

Wendi Xiang, Vice President | 相文迪  副总裁

YAFO Capital (Shanghai) 雅法资本

Mobile: +86-13733685995

Email: wxiang@yafocapital.com

Web: www.yafocapital.com

                                              ChemPartner Team

                                             Global Law Office Booth

                                              YAFO Team At BIO Booth

                                                  Meeting During BIO